GH Research PLC is a clinical-stage biopharmaceutical company. It dedicated to treat psychiatric and neurological disorders. The company's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. GH Research PLC is based in DUBLIN.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-35.59M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.30 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -15.48% |
Return on Assets (Trailing 12 Months) | -15.01% |
Current Ratio (Most Recent Fiscal Quarter) | 24.49 |
Quick Ratio (Most Recent Fiscal Quarter) | 24.49 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $4.94 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.21 |
Earnings per Share (Most Recent Fiscal Year) | $-0.68 |
Diluted Earnings per Share (Trailing 12 Months) | $-0.68 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 52.03M |
Free Float | 30.38M |
Market Capitalization | $571.79M |
Average Volume (Last 20 Days) | 0.12M |
Beta (Past 60 Months) | 0.84 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 41.60% |
Percentage Held By Institutions (Latest 13F Reports) | 56.90% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |